Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Direxion Daily S&P 500 Bull 3X Shares (SPXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Direxion Daily S&P 500 Bull 3X Shares — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $360.57 (market cap $9.43B), while Direxion Daily S&P 500 Bull 3X Shares trades at $295.65. Which is the better fit depends on your goals.
| BIO | SPXL | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $356.25 | $296.39 |
52-Week Low | $241.71 | $170.20 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Rad Laboratories (BIO) trades at $357.58, up 0.86% today, near its 52-week high. The stock shows a bullish technical trend with strong moving average signals, though oscillators indicate overbought conditions. Fundamentally, the company reported a Q2 2026 earnings beat with EPS of $2.62 versus $1.75 expected, and net income for 2025 reached $759.9 million, a significant recovery from prior years. Analyst sentiment is positive with a consensus buy rating and a $350 price target, though the P/E ratio of 43.39 suggests a premium valuation.
The outlook for BIO is cautiously optimistic, driven by earnings momentum and improving cash flow, but risks include high valuation, competitive pressures in life sciences, and reliance on academic research markets. Upside potential exists if international revenue trends strengthen, but investors should monitor margin sustainability and debt levels, which have improved but remain a focus.
SPXL, a leveraged ETF tracking the S&P 500, trades at $295.99, down 0.07% on the day, with technical indicators showing a bullish moving average trend but overbought RSI signals. The ETF reflects the S&P 500's record highs, driven by strong corporate earnings and AI optimism, though valuation concerns persist. Recent news highlights mixed sentiment, with JPMorgan raising its S&P 500 target to 8,000 while some warn of overvaluation risks.
The outlook for SPXL hinges on S&P 500 performance, offering amplified gains in a bullish market but heightened losses in downturns. Key opportunities include continued AI-driven earnings growth, while risks involve market volatility, inflation reports, and potential pullbacks from elevated levels. Investors should weigh leverage effects against broader index trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Direxion Daily S&P 500 Bull 3X Shares
SPXL aims for 300% of the S&P 500's daily performance. It uses swaps and futures to provide 3x leverage, making it a high-risk tool for short-term traders. Due to daily resets, it is prone to volatility decay and is not intended for long-term holding.
Read more on SPXL →
